Pfizer Pharmaceuticals and Valneva are in Phase 3 development of a potential vaccine against the bacteria present in deer ticks that causes Lyme disease. A clinical trial of the promising vaccine will take place on Martha’s Vineyard, which has one of the highest percentages of tick-borne illnesses in the world.

Volunteers above the age of five are being sought for the trial, scheduled to begin in August, and will receive shots of the potential vaccine at trailers stationed around the Vineyard.

Phase one and two of Pfizer’s research tested the safety and efficacy of the vaccine. The third phase will measure the extent of protection.